Benzene Ring Containing Patents (Class 514/637)
  • Patent number: 10912297
    Abstract: The present invention relates phenoxyhalogenphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to an agrochemical formulation for this purpose, comprising the phenoxyhalogenphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 9, 2021
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Stefan Hillebrand, Mazen Es-Sayed, Peter Dahmen, Ulrike Wachendorff-Neumann, Stephane Brunet
  • Patent number: 9309191
    Abstract: An amidine compound represented by formula (1) wherein R1, R2, R3, R4 and R5 are the same or different and represent a C1 to C5 alkyl group optionally having one or more halogen atoms or the like; R6 and R7 are a hydrogen atom or the like; R8 and R9 are the same or different and represent a C1 to C3 alkyl group optionally having one or more halogen atoms or the like; and R10 and R11 are the same or different and represent a C1 to C6 alkyl group optionally having one or more halogen atoms or the like, has an excellent control effect on plant diseases.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 12, 2016
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Hiroto Tamashima
  • Publication number: 20150038480
    Abstract: The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.
    Type: Application
    Filed: May 29, 2012
    Publication date: February 5, 2015
    Applicants: UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED, THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
    Inventors: Aaron Michels, Maki Nakayama, David Ostrov
  • Publication number: 20150031635
    Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    Type: Application
    Filed: June 30, 2014
    Publication date: January 29, 2015
    Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
  • Publication number: 20140315898
    Abstract: The present invention relates to novel N-arylamide-substituted trifluoroethyl sulfide derivatives of the formula (I) in which X1, X2, X3, X4, R1, R2, R3, n have the meanings given in the description—to their use as acaricides and insecticides for controlling animal pests and to processes and intermediates for their preparation
    Type: Application
    Filed: December 12, 2012
    Publication date: October 23, 2014
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Adeline Koehler, Bernd Alig, Angela Becker, Arnd Voerste, Ulrich Goergens, Reiner Fischer, Wahed Ahmed Moradi, Silvia Cerezo-Galvez, Julia Johanna Hahn, Kerstin Ilg, Hans-Georg Schwarz, Takuya Gomibuchi, Masahito Ito, Daiei Yamazaki, Katsuhiko Shibuya, Eiichi Shimojo
  • Publication number: 20140309195
    Abstract: Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration. Also provided herein are methods for promoting skin regeneration and wound healing.
    Type: Application
    Filed: January 8, 2014
    Publication date: October 16, 2014
    Applicant: INTERNATIONAL STEM CELL CORPORATION
    Inventors: Rodolfo Gonzalez, Maxim Poustovoitov, Ruslan Semechkin
  • Publication number: 20140288059
    Abstract: PAD4 inhibitory compositions and methods for their use in treatment of cancer and autoimmune disease are provided according to embodiments of the present invention.
    Type: Application
    Filed: April 25, 2014
    Publication date: September 25, 2014
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Gong Chen, Yanming Wang, Pingxin Li, Jing Hu, Shu Wang, Yuji Wang
  • Publication number: 20140206629
    Abstract: The invention relates to inhibition of SDF-1? expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-? stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provided are methods for treating or ameliorating a musculoskeletal disorder.
    Type: Application
    Filed: February 17, 2012
    Publication date: July 24, 2014
    Applicant: RHODE ISLAND HOSPITAL
    Inventor: Theodore A. Blaine
  • Publication number: 20140200225
    Abstract: A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors and are useful in the treatment of matriptase dependent conditions, particularly cancer.
    Type: Application
    Filed: March 27, 2014
    Publication date: July 17, 2014
    Applicant: ORION CORPORATION
    Inventors: Rajeev GOSWAMI, Anil Kumar VUPPALA, Ramesh VELUDANDI, Ramesh SISTLA, Chakshusmathi GHADIYARAM, Muralidhara RAMACHANDRA
  • Patent number: 8748468
    Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I:
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: June 10, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: David Loury, Tarak Mody
  • Publication number: 20140155420
    Abstract: The invention provides small molecule inhibitors of EYA2 phosphatase activity and EYA2 binding to Six1. These inhibitors are proposed for use in methods of treating cancer in a subject, such as those involving Six1 and/or EYA2 disregulation. In some embodiments, the invention further provides for the administration of a second cancer therapy to the subject.
    Type: Application
    Filed: January 10, 2012
    Publication date: June 5, 2014
    Applicants: The Regents of the University of Colorado, a body corporate, Department of Health and Human Services
    Inventors: Rui Zhao, Heide L. Ford, Noel Southall, Erika Englund, Samarjit Patnaik, Marc Ferrer, Wei Zheng, Seameen Dehdashti, Juan Marugan
  • Publication number: 20140051712
    Abstract: The invention describes pharmaceutical agents capable of crossing the blood brain barrier to protect against organophosphate pesticides and nerve agents or other electrophiles by reactivating inhibited cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) and other proteins in the peripheral and central nervous system.
    Type: Application
    Filed: December 16, 2011
    Publication date: February 20, 2014
    Inventors: John R. Cashman, Jarosiaw Kalisiak
  • Publication number: 20140044799
    Abstract: The present invention concerns a molecular signature of cutaneous pigmentary spots, comprising the genes MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2, and various applications of this signature. In particular, the invention concerns a method for characterizing a known or suspected pigmentary spot in a human being, comprising comparing the levels of expression in skin samples obtained from said spot and from adjacent undamaged skin, of at least one dermal gene linked to matrix remodelling or to its extracellular proteoglycan and glycoprotein components, selected from the list constituted by the genes MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2. The invention also concerns methods for evaluating the efficacy of a pigmentary spot treatment, cosmetic and therapeutic methods for the treatment of pigmentary spots, and various modulators for said genes, and their use.
    Type: Application
    Filed: April 20, 2012
    Publication date: February 13, 2014
    Applicant: L'OREAL
    Inventors: Francoise Bernerd, Christine Duval, Olivier De Lacharriere, Stephanie Nouveau, Xavier Marat
  • Publication number: 20130296436
    Abstract: An amidine compound represented by formula (1): wherein R1 represent a C1-C11 fluoroalkyl group, a C3-C11 fluoroalkenyl group or a C3-C11 fluoroalkynyl group; R2 represent a C1-C3 alkyl group; R3 represent a C1-C3 alkyl group; R4 represent a C3-C6 cycloalkyl group or a C1-C6 alkyl group optionally having one or more halogens and R5 represent a C3-C6 cycloalkyl group or a C1-C6 alkyl group optionally having one or more halogens, said compound having excellent plant disease controlling effect.
    Type: Application
    Filed: December 20, 2011
    Publication date: November 7, 2013
    Inventors: Tohru Inoue, Yoshihiko Nokura
  • Patent number: 8552046
    Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: October 8, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: David Loury, Norbert Purro
  • Patent number: 8519003
    Abstract: The present invention relates to phenoxyphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Grant
    Filed: March 8, 2008
    Date of Patent: August 27, 2013
    Assignee: Bayer Cropscience AG
    Inventors: Klaus Kunz, Ralf Dunkel, Jörg Nico Greul, Kerstin Ilg, Darren James Mansfield, Wahed Ahmed Moradi, Thomas Seitz, Peter Dahmen, Ulrike Wachendorff-Neumann, Arnd Voerste
  • Patent number: 8507493
    Abstract: The present invention relates to inhibitors of 11-?-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: August 13, 2013
    Assignee: AbbVie Inc.
    Inventors: Sridhar Peddi, Meena V. Patel, Jeffrey J. Rohde
  • Publication number: 20130157851
    Abstract: New phenylamidines are described, having general formula (I): and their use for the control of phytopathogenic fungi.
    Type: Application
    Filed: August 18, 2011
    Publication date: June 20, 2013
    Applicant: ISAGRO S.P.A.
    Inventors: Marilena Gusmeroli, Lucio Filippini, Franco Pellacini, Paolo Bravini, Alexia Elmini, Matteo Santino Vazzola, Christian Badaracco
  • Patent number: 8436049
    Abstract: Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid molecule, thereby treating the disease. In additional examples, the method comprises administration of a compound that disrupts binding of muscleblind-like proteins to an RNA nucleotide repeat expansion. Compounds for use in the disclosed method include pentamidine or heptamidine or derivatives thereof. Representative compounds are described herein.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: May 7, 2013
    Assignee: State of Oregon Acting By and Through the State Board of Higher Education on behalf of the University of Oregon
    Inventors: John Andrew Berglund, M. Bryan Warf, Catherine Matthys, Michael M. Haley, Cameron L. Hilton
  • Publication number: 20130102662
    Abstract: The present invention relates to methods and compositions that inhibit the effects of nitric oxide for inhibiting post-traumatic immunodepression. It is based, at least in part, on the discovery that, in a murine model system of trauma, genetic or chemical reduction of nitric oxide inhibited the development of immunodepression. Accordingly, the present invention provides for methods and compositions to be administered to subjects, post-trauma, that inhibit the effects of nitric oxide by inhibiting inducible nitric oxide synthase (iNOS) and/or scavenge nitric oxide.
    Type: Application
    Filed: December 6, 2012
    Publication date: April 25, 2013
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventor: University of Pittsburgh - of the Commonwealth System of Higher Education
  • Patent number: 8362264
    Abstract: Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: January 29, 2013
    Assignee: Dendreon Corporation
    Inventors: Sateesh K. Natarajan, Ofir Moreno, Thomas J. Graddis, David F. Duncan, Reiner Laus, Feng Chen
  • Publication number: 20120329870
    Abstract: Described herein is the use of ribonucleotide reductase inhibitors in the prevention or treatment of restenosis and other vascular proliferative disorders.
    Type: Application
    Filed: September 16, 2011
    Publication date: December 27, 2012
    Inventors: Howard L. Elford, Arturo J. Cardounel
  • Publication number: 20120255502
    Abstract: A method of treatment and a package that is designed to accomplish this. The package provides the pet owner with a pack containing individual doses of topically applied medications pre-packaged with an oral taste treat. The topically applied medication contains at least one pharmaceutically active ingredient selected from the group of chemical families comprising phenylpyrazoles, macrocyclic lactones, neonicotinoids, synthetic pyrethroids, insect growth regulators, amidines, semicarbazones, spinosyns, octadepsipeptides, and pyrazinoisoquinolines, or any combination thereof. The treat can be administered either before the topically applied treatment is given so as to relax and distract the pet, or after the treatment is given so as to reward the pet and help it forget the stress of treatment. The treat can also be shaped to signify the type of animal to be treated.
    Type: Application
    Filed: March 29, 2012
    Publication date: October 11, 2012
    Applicant: ALLEVA ANIMAL HEALTH LIMITED
    Inventor: Robert HOLMES
  • Patent number: 8252958
    Abstract: The invention concerns the use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells, said derivatives corresponding to formula (I), wherein: R?H or C1 and the phenyl group comprises two substituents, or a pharmaceutically acceptable salt of said derivatives.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: August 28, 2012
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Poitiers
    Inventors: Frederic Becq, Deborah Triboullard, Marc Blondel
  • Patent number: 8242161
    Abstract: The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an IGR compound, an avermectin or milbemycin derivative, or a pyrethroid insecticides, and anthelmintics, such as benzimidazoles and imidazothiazoles. The inventive formulation provides a larger duration of parasite control at a faster rate of control. The inventive formula remains effective up to three months from the first application. Moreover, the inventive formulations prevent tick attachment to the animal, thereby providing protection against tick borne diseases. The ectoparasites which may be controlled, treated or prevented by the present invention includes ticks, fleas, mites, mange, lice, mosquitoes, flies and cattle grubs.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: August 14, 2012
    Assignee: Merial Limited
    Inventors: Albert Boeckh, Luiz Gustavo Cramer, Mark D. Soll
  • Publication number: 20120129894
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: May 19, 2011
    Publication date: May 24, 2012
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Patent number: 8183414
    Abstract: The present invention provides compounds which are N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds and are subtype selective modulators of alpha 2B or alpha 2B and alpha 2C adrenoreceptors and are selected from the group of compounds represented by the formula
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 22, 2012
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Janet A. Takeuchi, Ling Li, Todd M. Heidelbaugh, Phong X. Nguyen, Evelyn G. Corpuz, Wenkui K Fang, Santosh C. Sinha, Michael E. Garst
  • Patent number: 8183296
    Abstract: The present invention relates to 2,5-di-substituted-4-phenyloxy-substituted-phenyl-amidine derivatives of formula (I) in which the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of phytopathogenic fungi or damaging insects, notably of plants, using these compounds or compositions.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: May 22, 2012
    Assignee: Bayer Cropscience AG
    Inventors: Peter Luemmen, Klaus Kunz, Jörg Greul, Oliver Guth, Benoît Hartmann, Kerstin Ilg, Wahed Ahmed Moradi, Thomas Seitz, Darren Mansfield, Jean-Pierre Vors, Peter Dahmen, Arnd Voerste, Ulrike Wachendorff-Neumann, Marie-Claire Grosjean-Cournoyer, Mark Drewes, Ralf Dunkel, Ronald Ebbert
  • Publication number: 20120122678
    Abstract: The present invention relates to 3-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Application
    Filed: January 26, 2012
    Publication date: May 17, 2012
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Klaus KUNZ, Ralf Dunkel, Jörg Nico Greul, Kerstin Ilg, Birgit Kuhn, Wahed Ahmed Moradi, Thomas Seitz, Darren James Mansfield, Oliver Guth, Peter Dahmen, Ulrike Wachendorff-Neumann, Arnd Voerste, Dale Robert Mitchell, Tom Hough, Jean-Pierre Vors
  • Patent number: 8119640
    Abstract: The present disclosure provides for compounds, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders associated with the Hh pathway.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: February 21, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: James K. Chen, Joel M. Hyman, Cory A. Ocasio
  • Publication number: 20110237679
    Abstract: Compounds, salts thereof, and tautomers thereof are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: December 9, 2009
    Publication date: September 29, 2011
    Applicant: CYTOKINE PHARMASCIENCES, INC.
    Inventor: Thais M. Sielecki-Dzurdz
  • Patent number: 8008352
    Abstract: Pentafluorosulfanylbenzoylguanidines, of the formula I and II in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: August 30, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventor: Heinz-Werner Kleemann
  • Patent number: 7947741
    Abstract: This invention provides for efflux pump inhibitors to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens, novel efflux pump inhibitors, combined dosage forms of efflux pump inhibitors with an antimicrobial, and novel medical methods.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: May 24, 2011
    Assignee: Mpex Pharmaceuticals, Inc.
    Inventors: Keith Bostian, Tomasz Glinka, Olga Lomovskaya, Mark Surber
  • Publication number: 20110118325
    Abstract: This invention provides REL inhibitors which interfere with the DNA binding capacity of a REL protein. Additionally this invention provides methods of treating, abrogating, or preventing diseases which respond with a positive clinical score to a REL inhibitor. Methods of identifying REL inhibitor based on a REL protein three dimensional model are described.
    Type: Application
    Filed: January 7, 2009
    Publication date: May 19, 2011
    Inventors: Youhai H. Chen, Ramachandran Murali, Jing Sun
  • Patent number: 7928137
    Abstract: Compounds of formula I in which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: April 19, 2011
    Assignee: Tularik Limited
    Inventors: John Walter Liebeschuetz, William Alexander Wylie, Bohdan Waszkowycz, Christopher William Murray, Andrew David Rimmer, Pauline Mary Welsh, Stuart Donald Jones, Jonathan Michael Ernest Roscoe, Stephen Clinton Young, Phillip John Morgan
  • Publication number: 20110015201
    Abstract: The present disclosure provides for compounds, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders associated with the Hh pathway.
    Type: Application
    Filed: February 12, 2009
    Publication date: January 20, 2011
    Inventors: James K. Chen, Joel M. Hyman, Cory A. Ocasio
  • Publication number: 20110003826
    Abstract: This invention relates to new chemical compounds, application of these compounds as anticoagulants, pharmaceutical compositions, and plasma-substituting solutions on their basis, and can be used for treating thromboembolic complications of diseases such as myocardial infarction, stroke, and thrombosis of deep veins or a pulmonary artery; and for preventing hypercoagulation conditions in consequence of injuries, surgeries, sepsis, various obstetric pathologies, in disaster medicine, resuscitation, and so on.
    Type: Application
    Filed: June 27, 2008
    Publication date: January 6, 2011
    Applicant: Obschestvo S Organichennoi Otvetsttvennoctiyu "Bio
    Inventors: Elena Ivanovna Sinauridze, Fazoil Inoyatovich Ataullakhanov, Andrey Alexandrovich Butylin, Vladimir Borisovich Sulimov, Alexey Nickolayevich Romanov, Alexey Alexeevich Bogolyubov, Yury Vladimirovich Kuznetsov, Irina Vladimirovna Gribkova, Alexander Sergeevich Gorbatenko, Olga Anatolievna Kondakova
  • Publication number: 20100267738
    Abstract: The present invention relates to inhibitors of 11-?-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Application
    Filed: April 20, 2010
    Publication date: October 21, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Sridhar Peddi, Meena V. Patel, Jeffrey J. Rohde
  • Publication number: 20100266581
    Abstract: Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions.
    Type: Application
    Filed: March 12, 2010
    Publication date: October 21, 2010
    Applicant: DUKE UNIVERSITY
    Inventors: JONATHAN S. STAMLER, LIMIN LIU
  • Patent number: 7799947
    Abstract: The invention relates to a compound of formula (I) having use for in vivo imaging of the NR2B subtype of the NMDA receptor.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: September 21, 2010
    Assignee: Hammersmith Imanet Limited
    Inventors: Erik Arstad, Gjermund Henriksen
  • Publication number: 20100189669
    Abstract: Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.
    Type: Application
    Filed: January 25, 2010
    Publication date: July 29, 2010
    Inventor: Tomohiro Hakozaki
  • Publication number: 20100167926
    Abstract: The present invention relates to 3-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Application
    Filed: March 4, 2008
    Publication date: July 1, 2010
    Applicant: Bayer CropScience AG
    Inventors: Klaus Kunz, Ralf Dunkel, Jorg Nico Greul, Kerstin Ilg, Birgit Kuhn, Wahed Ahmed Moradi, Thomas Seitz, Darren James Mansfield, Oliver Guth, Peter Dahmen, Ulrike Wachendorff-Neumann, Arnd Voerste, Robert Dale Mitchell, Tom Hough
  • Publication number: 20100119512
    Abstract: The present invention provides methods for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.
    Type: Application
    Filed: January 25, 2008
    Publication date: May 13, 2010
    Applicant: Joslin Diabetes Center
    Inventors: Edward P. Feener, Lloyd P. Aiello
  • Publication number: 20100120615
    Abstract: The present invention relates to 4-cycloalkyl- or 4-aryl-substituted phenoxyphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Application
    Filed: March 8, 2008
    Publication date: May 13, 2010
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Klaus Kunz, Ralf Dunkel, Jörg Nico Greul, Oliver Guth, Kerstin Ilg, Darren James Mansfield, Wahed Ahmed Moradi, Thomas Seitz, Peter Dahmen, Ulrike Wachendorff-Neumann, Arnd Voerste, Jean-Pierre Vors
  • Publication number: 20100105552
    Abstract: The present invention relates to phenoxyphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Application
    Filed: March 8, 2008
    Publication date: April 29, 2010
    Inventors: Klaus Kunz, Ralf Dunkel, Joerg Nico Greul, Kerstin Ilg, Darren James Mansfield, Wahed Ahmed Morradi, Thomas Seilz, Peter Dahmen, Ulrike Wachendorff Neumann, Arnd Voerste
  • Publication number: 20100093534
    Abstract: The present invention relates to fluoroalkylphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Application
    Filed: March 8, 2008
    Publication date: April 15, 2010
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Klaus Kunz, Jörg Nico Greul, Ulrich Heinemann, Darren James Mansfield, Amos Mattes, Oswald Ort, Thomas Seitz, Wahed Ahmed Moradi, Ulrike Wachendorff-Neumann, Peter Dahmen, Arnd Voerste
  • Publication number: 20100093533
    Abstract: The present invention relates to 3,4-disubstituted phenoxyphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Application
    Filed: March 4, 2008
    Publication date: April 15, 2010
    Applicant: Bayer CropSceince AG
    Inventors: Klaus Kunz, Ralf Dunkel, Jörg Nico Greul, Stefan Hillebrand, Kerstin Ilg, Darren James Mansfield, Wahed Ahmed Moradi, Thomas Seitz, Peter Dahmen, Ulrike Wachendorff-Neumann, Arnd Voerste, Jean-Pierre Vors, Oliver Guth
  • Patent number: 7667077
    Abstract: A new class of fluorinated or polyhalogenated triazapentadienes are disclosed. The synthesized triazapentadienes are thermally stable, soluble in typical solvents and have several metal binding sites for complexation with metal ions. The compounds are prepared as colorless crystalline solids. Synthesis takes advantage of a reaction with triethylamine. Synthesized triazapentadienes (with and without complexed metals) inhibit bacterial growth of both Gram positive and Gram-negative bacteria.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: February 23, 2010
    Assignee: Board of Regents, The University of Texas
    Inventors: H. V. Rasika Dias, Lorraine G. Van Waasbergen, Jaime A. Flores
  • Publication number: 20100029588
    Abstract: The present invention relates to oxime ether-, hydrazone- or azomethine-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the amidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Application
    Filed: March 8, 2008
    Publication date: February 4, 2010
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Thomas Seitz, Klaus Kunz, Wahed Ahmed Moradi, Jörg Nico Greul, Darren James Mansfield, Urlich Heinemann, Amos Mattes, Oswald Ort, Jean-Pierre Vors, Peter Dahem, Ulrike Wachendorff-Neumann, Arnd Voerste
  • Patent number: 7592374
    Abstract: A composition of matter is disclosed that comprises a compound of the formula: wherein R1 is selected from the group consisting of unsubstituted and substituted biphenyl moieties, unsubstituted and substituted fluorenyl moieties, unsubstituted and substituted carbazolyl moieties, and unsubstituted and substituted pyridyl moieties; and R2 is hydrogen or alkyl. The compositions are useful as insecticides, acaricides, and fungicides.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: September 22, 2009
    Assignee: Crompton Corporation
    Inventors: Mark A. Dekeyser, Sheldon B. Park, Paul T. McDonald